Molecular localization of human IgG anti-F(ab′)2 reactivity with variable- and constant-region λ light-chain epitopes
Identifieur interne : 000127 ( Istex/Curation ); précédent : 000126; suivant : 000128Molecular localization of human IgG anti-F(ab′)2 reactivity with variable- and constant-region λ light-chain epitopes
Auteurs : Ralph C. Williams Jr. [États-Unis] ; Christine C. Malone [États-Unis] ; Franco Silvestris [États-Unis] ; Alan Solomon [États-Unis]Source :
- Journal of Clinical Immunology [ 0271-9142 ] ; 1995-11-01.
English descriptors
- KwdEn :
- Teeft :
- Affinity chromatography, Affinity measurements, Alanine, Alanine substitution strategy, Amino, Amino acid, Amino acid residues, Amino acids, Antibody, Antibody preparations, Antigenic, Antigenic determinants, Antigenic epitopes, Arth rheum, Average affinity, Average elisa reactivity, Bence jones protein, Boldface type, Clin, Clin immunol immunopathol, Clinical immunology, Competition elisa, Conformational epitopes, Control peptide, Disease activity, Elisa, Elisa reactivity, Elisa reactivity profile, Epitope, Framework regions, Glycine, Higher values, Human antibodies, Idiotypic networks, Immunodominant, Immunodominant residues, Immunol, Immunol methods, Immunology, Inhibition enzyme immunoassay, Inhibition studies, Light chain, Light chain epitopes, Light chains, Linear epitopes, Linear regions, Mabs, Major importance, Malone, Maximum binding concentration, Maximum inhibition, Molecular localization, Monoclonal, Monoclonal antibodies, Normal donor, Normal individuals, Normal subject, Normal subjects, Peptide, Polypropylene pins, Positive reactions, Reactive, Reactive epitopes, Reactive peaks, Reactive peptides, Reactive profile, Reactive regions, Reactivity profile, Reactivity profiles, Reagent, Residue, Rheumatoid, Rheumatoid arthritis, Rheumatoid factors, Room temperature, Serial dilutions, Silvestris, Strong reactivity, Substitution, Substitution technique, Synthetic peptides, Systemic lupus erythematosus, Variable region.
Abstract
Abstract: Human IgG antibodies reacting with antigenic determinants on F(ab′)2 fragments represent generic antiidiotypic antibodies present in the serum of normal individuals. Additionally, the titers of these antibodies in the sera of patients with systemic lupus erythematosus (SLE) are inversely related to disease activity. Because these autoantibodies recognize predominantly light chain-related epitopes, especially λ type, we synthesized constant (C)λ- and variable (V)λ-related overlapping 7-mer peptides on polypropylene pins to determine anti-F(ab′)2-reactive epitopes on humanλ light chains. ELISA reactivity of affinity-purified anti-F(ab′)2 antibodies obtained from normal individuals and from patients with SLE, as well as murine anti-human light-chain monoclonal antibodies specific for Cλ and Vλ subgroup-related determinants, was tested using the overlapping 7-mers of humanλ light-chain sequence. The patterns of reactivity against Cλ-related peptides were similar in both normal and SLE-derived anti-F(ab′)2 antibodies. However, reactivity profiles against Vλ-related peptides were distinctively different between the normal and the SLE-associated anti-F(ab′)2 autoantibodies. A decrease in reactivity among the SLE IgG anti-F(ab′)2 antibodies was noted for particular amino acid Vλ complementarity-determining region (CDR) residues, including glycine at positions 27 and 54, alanine at 16 and 37, and tyrosine at 28 and 91. This different pattern of reactivity from normal may indicate that in SLE there is a failure of antiidiotypic control mechanisms, as reflected by a defect in production of antibody to immunodominant Vλ CDR residues.
Url:
DOI: 10.1007/BF01541325
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000127
Links to Exploration step
ISTEX:0D77452CF4BC31C4F0AEB5E42CBC0B38CEDCF2E1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular localization of human IgG anti-F(ab′)2 reactivity with variable- and constant-region λ light-chain epitopes</title>
<author><name sortKey="Williams Jr, Ralph C" sort="Williams Jr, Ralph C" uniqKey="Williams Jr R" first="Ralph C." last="Williams Jr.">Ralph C. Williams Jr.</name>
<affiliation wicri:level="2"><mods:affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Malone, Christine C" sort="Malone, Christine C" uniqKey="Malone C" first="Christine C." last="Malone">Christine C. Malone</name>
<affiliation wicri:level="2"><mods:affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Silvestris, Franco" sort="Silvestris, Franco" uniqKey="Silvestris F" first="Franco" last="Silvestris">Franco Silvestris</name>
<affiliation wicri:level="2"><mods:affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Solomon, Alan" sort="Solomon, Alan" uniqKey="Solomon A" first="Alan" last="Solomon">Alan Solomon</name>
<affiliation wicri:level="2"><mods:affiliation>Human Immunology and Cancer Program, Department of Medicine, University of Tennessee, Knoxville, Tennessee</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Human Immunology and Cancer Program, Department of Medicine, University of Tennessee, Knoxville</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0D77452CF4BC31C4F0AEB5E42CBC0B38CEDCF2E1</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1007/BF01541325</idno>
<idno type="url">https://api.istex.fr/ark:/67375/1BB-6S3PFTD3-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000127</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000127</idno>
<idno type="wicri:Area/Istex/Curation">000127</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Molecular localization of human IgG anti-F(ab′)2 reactivity with variable- and constant-region λ light-chain epitopes</title>
<author><name sortKey="Williams Jr, Ralph C" sort="Williams Jr, Ralph C" uniqKey="Williams Jr R" first="Ralph C." last="Williams Jr.">Ralph C. Williams Jr.</name>
<affiliation wicri:level="2"><mods:affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Malone, Christine C" sort="Malone, Christine C" uniqKey="Malone C" first="Christine C." last="Malone">Christine C. Malone</name>
<affiliation wicri:level="2"><mods:affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Silvestris, Franco" sort="Silvestris, Franco" uniqKey="Silvestris F" first="Franco" last="Silvestris">Franco Silvestris</name>
<affiliation wicri:level="2"><mods:affiliation>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Solomon, Alan" sort="Solomon, Alan" uniqKey="Solomon A" first="Alan" last="Solomon">Alan Solomon</name>
<affiliation wicri:level="2"><mods:affiliation>Human Immunology and Cancer Program, Department of Medicine, University of Tennessee, Knoxville, Tennessee</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Human Immunology and Cancer Program, Department of Medicine, University of Tennessee, Knoxville</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Journal of Clinical Immunology</title>
<title level="j" type="abbrev">J Clin Immunol</title>
<idno type="ISSN">0271-9142</idno>
<idno type="eISSN">1573-2592</idno>
<imprint><publisher>Kluwer Academic Publishers</publisher>
<pubPlace>Dordrecht</pubPlace>
<date type="published" when="1995-11-01">1995-11-01</date>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="349">349</biblScope>
<biblScope unit="page" to="362">362</biblScope>
</imprint>
<idno type="ISSN">0271-9142</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0271-9142</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Idiotypes (Ids)</term>
<term>anti-F(ab′)2 antibodies</term>
<term>anti-Ids</term>
<term>autoantibodies</term>
<term>systemic lupus erythematosus</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Affinity chromatography</term>
<term>Affinity measurements</term>
<term>Alanine</term>
<term>Alanine substitution strategy</term>
<term>Amino</term>
<term>Amino acid</term>
<term>Amino acid residues</term>
<term>Amino acids</term>
<term>Antibody</term>
<term>Antibody preparations</term>
<term>Antigenic</term>
<term>Antigenic determinants</term>
<term>Antigenic epitopes</term>
<term>Arth rheum</term>
<term>Average affinity</term>
<term>Average elisa reactivity</term>
<term>Bence jones protein</term>
<term>Boldface type</term>
<term>Clin</term>
<term>Clin immunol immunopathol</term>
<term>Clinical immunology</term>
<term>Competition elisa</term>
<term>Conformational epitopes</term>
<term>Control peptide</term>
<term>Disease activity</term>
<term>Elisa</term>
<term>Elisa reactivity</term>
<term>Elisa reactivity profile</term>
<term>Epitope</term>
<term>Framework regions</term>
<term>Glycine</term>
<term>Higher values</term>
<term>Human antibodies</term>
<term>Idiotypic networks</term>
<term>Immunodominant</term>
<term>Immunodominant residues</term>
<term>Immunol</term>
<term>Immunol methods</term>
<term>Immunology</term>
<term>Inhibition enzyme immunoassay</term>
<term>Inhibition studies</term>
<term>Light chain</term>
<term>Light chain epitopes</term>
<term>Light chains</term>
<term>Linear epitopes</term>
<term>Linear regions</term>
<term>Mabs</term>
<term>Major importance</term>
<term>Malone</term>
<term>Maximum binding concentration</term>
<term>Maximum inhibition</term>
<term>Molecular localization</term>
<term>Monoclonal</term>
<term>Monoclonal antibodies</term>
<term>Normal donor</term>
<term>Normal individuals</term>
<term>Normal subject</term>
<term>Normal subjects</term>
<term>Peptide</term>
<term>Polypropylene pins</term>
<term>Positive reactions</term>
<term>Reactive</term>
<term>Reactive epitopes</term>
<term>Reactive peaks</term>
<term>Reactive peptides</term>
<term>Reactive profile</term>
<term>Reactive regions</term>
<term>Reactivity profile</term>
<term>Reactivity profiles</term>
<term>Reagent</term>
<term>Residue</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid factors</term>
<term>Room temperature</term>
<term>Serial dilutions</term>
<term>Silvestris</term>
<term>Strong reactivity</term>
<term>Substitution</term>
<term>Substitution technique</term>
<term>Synthetic peptides</term>
<term>Systemic lupus erythematosus</term>
<term>Variable region</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Human IgG antibodies reacting with antigenic determinants on F(ab′)2 fragments represent generic antiidiotypic antibodies present in the serum of normal individuals. Additionally, the titers of these antibodies in the sera of patients with systemic lupus erythematosus (SLE) are inversely related to disease activity. Because these autoantibodies recognize predominantly light chain-related epitopes, especially λ type, we synthesized constant (C)λ- and variable (V)λ-related overlapping 7-mer peptides on polypropylene pins to determine anti-F(ab′)2-reactive epitopes on humanλ light chains. ELISA reactivity of affinity-purified anti-F(ab′)2 antibodies obtained from normal individuals and from patients with SLE, as well as murine anti-human light-chain monoclonal antibodies specific for Cλ and Vλ subgroup-related determinants, was tested using the overlapping 7-mers of humanλ light-chain sequence. The patterns of reactivity against Cλ-related peptides were similar in both normal and SLE-derived anti-F(ab′)2 antibodies. However, reactivity profiles against Vλ-related peptides were distinctively different between the normal and the SLE-associated anti-F(ab′)2 autoantibodies. A decrease in reactivity among the SLE IgG anti-F(ab′)2 antibodies was noted for particular amino acid Vλ complementarity-determining region (CDR) residues, including glycine at positions 27 and 54, alanine at 16 and 37, and tyrosine at 28 and 91. This different pattern of reactivity from normal may indicate that in SLE there is a failure of antiidiotypic control mechanisms, as reflected by a defect in production of antibody to immunodominant Vλ CDR residues.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:0D77452CF4BC31C4F0AEB5E42CBC0B38CEDCF2E1 |texte= Molecular localization of human IgG anti-F(ab′)2 reactivity with variable- and constant-region λ light-chain epitopes }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |